Skip to main content
Premium Trial:

Request an Annual Quote

NIH Extends Subscription to BioBase's Proteome and Transfac Databases

NEW YORK (GenomeWeb News) — The National Institutes of Health has extended its subscription to BioBase’sProteome and its Transfac databases, the company said today.
 
The Proteome databases collect and organize publicly available species-specific sequence information for 20 species. The HumanPSD volume contains information about functions, roles, localization and modifications of human, mouse, and rat proteins and expression patterns across cells, tissues, tumors, and consequences of gene mutations in mice.
 
The Transfac database covers eukaryotic gene regulation and contains annotated information related to nearly 9,000 transcription factors. It also holds information for 18,000 transcription factor binding sites derived from nucleotide distribution matrices and 12,000 binding fragments from ChIP-on-chip experiments. 
 
Financial terms of the agreement were not released.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.